AbbVie has filed with the FDA to extend the uses of its bipolar disorder therapy Vraylar to include adjunctive therapy for major depressive disorder, part of a plan to build sales of the drug to peak ...

I've been writing and editing stories for almost two decades that help people use technology and productivity techniques to work better, live better, and protect their privacy and personal data. As ...